Q-omics provides the consensus-scored TRBV6-5 profile across patient tissues and cancer cell-line models. TRBV6-5 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, TRBV6-5 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, TRBV6-5 RNA expression shows 16,970 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KIRC, and LSCC as cancer lineages where TRBV6-5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRBV6-5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRBV6-5 survival associations across molecular data types. TRBV6-5 RNA expression shows survival associations in the most cancer types (27). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRBV6-5 RNA expression–survival associations across cancer types. High TRBV6-5 expression shows unfavorable associations in UVM, but favorable associations in SKCM, HNSC, CESC, LUAD and OV. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for TRBV6-5 RNA expression.
This table summarizes TRBV6-5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRBV6-5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRBV6-5 shows lower tumor expression in BLCA and LUSC and higher tumor expression in KIRC and BRCA. The KIRC box plot shows higher TRBV6-5 RNA expression in tumor versus normal tissue (log2 FC = +1.960, t-test p < 0.001).
This table shows molecular features associated with TRBV6-5 in patient tissues and cancer cell lines. In patient samples, TRBV6-5 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
